MIM
KERX

MetLife Investment Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

MetLife Investment Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-5,191
Closed -$17.6K – 2637
2018
Q3 		$17.6K Sell
5,191
-35,118
-87% -$127K ﹤0.01% 2393
2018
Q2 		$152K Hold
40,309
– – ﹤0.01% 2047
2018
Q1 		$165K Hold
40,309
– – ﹤0.01% 1994
2017
Q4 		$187K Buy
+40,309
New +$222K ﹤0.01% 1965

MetLife Investment Management's KERX Position: Q4 2018 in Review

MetLife Investment Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 5,191 shares — an estimated $17.6K sold.

MetLife Investment Management first reported a position in KERX in Q4 2017 and held it in 4 quarters. The position peaked at $187K in Q4 2017. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.

  • MetLife Investment Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
  • MetLife Investment Management sold 5,191 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $17.6K.
  • MetLife Investment Management first reported a position in Keryx Biopharmaceuticals Inc in Q4 2017 and held it in 4 quarters.
  • MetLife Investment Management's Keryx Biopharmaceuticals Inc position peaked at $187K in Q4 2017.
  • 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.

Based on MetLife Investment Management's 13F filing for Q4 2018, filed 14 Feb 2019.